1. Stem Cell/Wnt
  2. β-catenin

TD139 

Cat. No.: HY-19940 Purity: 99.39%
Handling Instructions

TD139 is a novel high-affinity inhibitor of the galectin-3 carbohydrate binding domain with a Kd of 14 nM.

For research use only. We do not sell to patients.

TD139 Chemical Structure

TD139 Chemical Structure

CAS No. : 1450824-22-2

Size Price Stock Quantity
1 mg USD 80 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 160 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 260 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
50 mg USD 940 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 1650 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

TD139 is a novel high-affinity inhibitor of the galectin-3 carbohydrate binding domain with a Kd of 14 nM.

IC50 & Target

Kd: 14 nM (galectin-3)[1]

In Vitro

TD139 is a novel synthetic inhibitor of galectin-3. TD139 has high affinity for galectin-3 with a Kd of 14 nM and 10 nM for galectin-1, but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N[1].

In Vivo

In primary lung AECs TD139 reduces TGF-β1–induced β-catenin translocation to the nucleus, with most of the β-catenin remaining at the cell surface. TD139 blocks TGF-β1–induced β-catenin phosphorylation. A marked reduction in fibrosis and β-catenin activation accompanied by decreased galectin-3 expression is observed in the lungs of WT mice treated with TD139[1]. Pretreatment of WT C57BL/6 mice with TD139 leads to the attenuation of liver injury and milder infiltration of IFNγ- and IL-17- and -4-producing CD4(+) T cells, as well as an increase in the total number of IL-10-producing CD4(+) T cells and F4/80(+) CD206(+) alternatively activates macrophages and preventes the apoptosis of liver-infiltrating MNCs[2].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.5417 mL 7.7084 mL 15.4169 mL
5 mM 0.3083 mL 1.5417 mL 3.0834 mL
10 mM 0.1542 mL 0.7708 mL 1.5417 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration
[2]

TD139 is prepared in saline.

Mice: The susceptibility to Con A-induced hepatitis in galectin-3-deficient mice is tested and the effects of pretreatment with a selective inhibitor of Gal-3 (TD139) in wild-type(WT) C57BL/6 mice are analyzed, as evaluated by a liver enzyme test, quantitative histology, mononuclear cell (MNC) infiltration, cytokine production, intracellular staining of immune cells, and percentage of apoptotic MNCs in the liver[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

648.64

Formula

C₂₈H₃₀F₂N₆O₈S

CAS No.

1450824-22-2

SMILES

O[[email protected]]([[email protected]@H](N1N=NC(C2=CC=CC(F)=C2)=C1)[[email protected]]([[email protected]@H](CO)O3)O)[[email protected]@H]3S[[email protected]]4[[email protected]@H]([[email protected]@H](N5N=NC(C6=CC=CC(F)=C6)=C5)[[email protected]]([[email protected]@H](CO)O4)O)O

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 1 mg/mL (Need ultrasonic); H2O: < 5 mg/mL; Ethanol: 0.1 mg/mL (Need ultrasonic and warming)

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

  • 竞价

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TD139
Cat. No.:
HY-19940
Quantity: